XML 35 R24.htm IDEA: XBRL DOCUMENT v3.22.2
Description of the Business and Liquidity (Details)
$ in Thousands, € in Millions
1 Months Ended 3 Months Ended 6 Months Ended 14 Months Ended
Jul. 30, 2021
USD ($)
Jul. 30, 2021
EUR (€)
May 11, 2021
USD ($)
tranche
Jul. 31, 2022
USD ($)
Mar. 31, 2022
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Jun. 30, 2022
USD ($)
Mar. 31, 2022
USD ($)
Jun. 30, 2021
USD ($)
Mar. 31, 2021
USD ($)
Jun. 30, 2022
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2022
USD ($)
Dec. 31, 2021
USD ($)
Liquidity                              
Net loss               $ 39,433 $ 19,361 $ 23,823 $ 27,141 $ 58,794 $ 50,964    
Accumulated deficit               469,499       469,499   $ 469,499 $ 410,705
Oaktree Capital Management LP Credit Agreement                              
Liquidity                              
Term of loan facility     5 years                        
Maximum borrowing capacity available under the credit agreement     $ 100,000                        
Number of tranches | tranche     4                        
Proceeds from Lines of Credit     $ 15,000   $ 30,000 $ 30,000               75,000  
Remaining borrowing capacity               25,000       25,000   25,000  
Additional borrowing capacity available, subject to certain milestone events     $ 25,000                        
Oaktree Capital Management LP Credit Agreement | Funding of the tranche A- 2 term loans until the funding of the tranche B term loans                              
Liquidity                              
Minimum liquidity to be maintained               $ 15,000       $ 15,000   $ 15,000  
PRV Asset Purchase Agreement                              
Liquidity                              
Amount of consideration to be paid by the acquirer to the Company upon closing of the asset purchase transaction       $ 110,000                      
BARDA Contract                              
Liquidity                              
Maximum amount to be awarded under the contract             $ 51,000                
Contract base period             2 years                
Amount of funding to be provided during contract base period             $ 21,000                
Amount of additional funding to be provided following successful completion of clinical trial and preclinical studies in base period             30,000                
Cost sharing, amount             33,000                
Cost sharing, BARDA amount             $ 51,000                
Contract period-of-performance             5 years                
Collaboration Agreement with Orion                              
Liquidity                              
Upfront fee received $ 29,600 € 25.0                          
R&D reimbursement and cash milestone payments to be received | €   € 97.0                          
Number of days from receipt of the final report, in which the collaboration agreement may be terminated 90 days 90 days                          
Percentage of upfront fee which must be refunded in the event of termination   75.00%                          
Term Loan Tranche B | Oaktree Capital Management LP Credit Agreement                              
Liquidity                              
Proceeds from Lines of Credit         $ 30,000